3 completed. 3 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 3 |
| Phase 2 | 3 | Completed 3 |
Follow Recurrent Anaplastic Large Cell Lymphoma: new trials by email Literature Review of Recurrent Anaplastic Large Cell Lymphoma trials Research Report on Recurrent Anaplastic Large Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas Anti-CD30/CD16A Monoclonal Antibody AFM13, Cyclophosphamide, Fludarabine - Recurrent Anaplastic Large Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 45 | 2020-07-18 | 2026-09-30 |
| Study of Pembrolizumab (MK-3475) in Combination With Romidepsin Pembrolizumab, Romidepsin - Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 38 | 2017-11-14 | 2026-10-28 |
| Lenalidomide Therapy After Chemotherapy & Stem Cell Transplant in Treating Chemotherapy Resistan Non-Hodgkin Lymphoma Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cytarabine - Anaplastic Large Cell Lymphoma, ALK-Negative, Recurrent Anaplastic Large Cell Lymphoma | Phase 1 / Phase 2 | Completed | University of Nebraska | 74 | 2009-11-12 | 2023-10-10 |
Lymphoma, Large-Cell, Anaplastic (3) · Lymphoma, T-Cell (2) · Mycosis Fungoides (2) · Immunoblastic Lymphadenopathy (1) · Lymphoma, B-Cell (1) · Lymphoma, Mantle-Cell (1) · Lymphoma, Non-Hodgkin (1) · Lymphoma, T-Cell, Cutaneous (1)
Hemic and Lymphatic Diseases (3) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Lymphatic Diseases (3) · Lymphoma (3) · Lymphoproliferative Disorders (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Lymphoma, Non-Hodgkin (2) · Lymphadenopathy (1) · Lymphoma, T-Cell (1) · Lymphoma, T-Cell, Cutaneous (1)
AFM13 (1) · CT-P10 (1) · Carmustine (1) · Cyclophosphamide (1) · Cytarabine (1) · Depsipeptides (1) · Etoposide (1) · Lactones (1) · Lenalidomide (1) · Melphalan (1) · Rituximab (1) · carmustine, poliferprosan 20 drug combination (1) · fludarabine (1) · fludarabine phosphate (1) · pembrolizumab (1)
M.D. Anderson Cancer Center (2) · University of Nebraska (1)
United States (3)
Julie Vose, MD, MBA (1) · Swaminathan P Iyer, MD (1) · Yago L Nieto (1)
P30CA036727 (1)